Query: hemostat

This page shows you your search results in order of date.

Order by Relevance | Date

Total 204 results found since Jan 2013.

Back Cover Image: Volume 34 Issue 9
Back Cover Caption: The cover image is based on the Technical NoteApplication Techniques of a Novel Hemostat in Cardiac Operations: HEMOBLAST by Brian Bruckner et al.,https://doi.org/10.1111/jocs.14171
Source: Journal of Cardiac Surgery - September 6, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Brian A. Bruckner, Uy Ngo, Mahesh Ramchandani, Erik Suarez, Samir Awad, Michael Reardon Tags: BACK COVER Source Type: research

Editorial Comment on: Evaluation of a Chitosan Hemostat in a Porcine Laparoscopic Partial Nephrectomy Model: A Pilot Study by Crofton et al. (From: Crofton A, Baldwin D, Alsyouf M, et al. J Endourol 2019 Epub ahead of print; DOI: 10.1089/end.2018.0801)
Journal of Endourology, Ahead of Print.
Source: Journal of Endourology - August 22, 2019 Category: Urology & Nephrology Authors: David S. Wang Source Type: research

Hemostasis and Bone Regeneration Using Chitosan/Gelatin-BCP Bi-layer Composite Material
The aim of the study was to determine the hemostatic activity of a composite bi-layered topical hemostat composed of electrospun gelatin loaded with bi-phasic calcium phosphate and chitosan layer and its effect on bone formation. Morphology of the composite hemostat and its individual components were observed using scanning electron microscopy. In vitro biocompatibility of the topical hemostat tested using preosteoblasts cells (MC3t3-E1) showed no adverse toxicity. Confocal microscopy of seeded cells showed good cell adhesion while 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay indicated 15% incre...
Source: ASAIO Journal - July 30, 2019 Category: Medical Devices Tags: Tissue Engineering/ Biomaterials Source Type: research

Application techniques of a novel hemostat in cardiac operations: HEMOBLAST
ConclusionHB is a novel powder ‐based multiple component hemostatic agent that promotes focal or large area hemostasis. We have presented the techniques of use that are important to the successful application of HB to facilitate hemostasis.
Source: Journal of Cardiac Surgery - July 26, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Brian A. Bruckner, Uy Ngo, Mahesh Ramchandani, Erik Suarez, Samir Awad, Michael Reardon Tags: SURGICAL TECHNIQUE Source Type: research

Contralateral C7 transfer combined with acellular nerve allografts seeded with differentiated adipose stem cells for repairing upper brachial plexus injury in rats.
This study was approved by the Animal Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University of China (approval No. 2016-150) in June 2016. PMID: 31290451 [PubMed]
Source: Cell Research - July 12, 2019 Category: Cytology Authors: Yang JT, Fang JT, Li L, Chen G, Qin BG, Gu LQ Tags: Neural Regen Res Source Type: research

Lymphostasis and Hemostasis in Body-Contouring Surgery Using a Polysaccharide Based Hemostat (4DryField PH)
Conclusions: This is the first prospective, monocentric, randomized study on 4DF in body-contouring surgery. The use of 4DF did not lead to a better postoperative outcome regarding hemostasis and lymphostasis. Potential benefits need further evaluation in high-volume studies.
Source: Plastic and Reconstructive Surgery Global Open - March 1, 2019 Category: Cosmetic Surgery Tags: Original Article Source Type: research

Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance
Conclusion: Our present study indicated, for the first time, that ABS could act against H. pylori. ABS is clinically used for the management of GI bleeding due to benign and malignant GI lesions. Thus, the possible anti-H. pylori effect of ABS shall expand the therapeutic spectrum of the drug in GI lesions in relation to H. pylori infection such as peptic ulser disease (PUD) and lymphoid tissue (MALT) lymphomagenesis. PMID: 30761849 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - February 16, 2019 Category: General Medicine Tags: Turk J Med Sci Source Type: research

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study
Conclusion: ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinical effects of ABS may be ascribed to the antierythroid aggregan actions of the drug. PMID: 30761848 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - February 16, 2019 Category: General Medicine Tags: Turk J Med Sci Source Type: research

Advanced Medical Solutions Group plc: Acquisition of Sealantis
Winsford, UK, 31 January 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces it has acquired Sealantis Limited ( “Sealantis”), a developer of an alginate-based tissue adhesive technology platform, for $US 25m (approximately £19m) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.Overview of SealantisSealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under developm...
Source: Medical Hemostat - February 1, 2019 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Investigation of efficiency of a novel, zinc oxide loaded TEMPO-oxidized cellulose nanofiber based hemostat for topical bleeding.
Abstract Lethal bleeding due to street accidents, natural calamities, orthopedic/dental surgeries, organ transplantation and household injuries, is the leading cause of morbidity and mortality. In the current study, zinc oxide (ZnO) was incorporated in TEMPO-oxidized cellulose nanofiber (TOCN) and polyethylene glycol (PEG) polymer system for hemorrhage control by freeze drying method. SEM and XRD data showed the presence of ZnO in the porous structure. FT-IR analysis showed that, successful conjugation occurs among the TOCN and PEG. The results revealed that, the incorporation of ZnO and higher concentrations of P...
Source: International Journal of Biological Macromolecules - December 8, 2018 Category: Biochemistry Authors: Shefa AA, Taz M, Hossain M, Kim YS, Lee SY, Lee BT Tags: Int J Biol Macromol Source Type: research

Experimental Evaluation of a New Tissue Factor-Based Topical Hemostat (TT-173) for Treatment of Hepatic Bleeding.
CONCLUSIONS: TT-173 shows favorable pharmacodynamic properties for improving hemostasis in partial liver resection which support further investigation of the product in this surgical indication. PMID: 30380352 [PubMed - as supplied by publisher]
Source: Journal of Investigative Surgery - November 2, 2018 Category: Surgery Tags: J Invest Surg Source Type: research

FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
The U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.“The device provides an additional, non-surgical option for treating upper and lower GI bleeding in certain patients, and may help reduce the risk of death from a GI bleed for many patients,” said Binita Ashar, M.D., director, division of surgical devices, in the FDA’s Center for Devices and R adiological Health.GI bleeding can occur in the upper GI tract (esophagus, stomach or small intestine) or the lower GI tract (colon and rectum). Causes of GI blee...
Source: Medical Hemostat - September 23, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

GRGDS-functionalized chitosan nanoparticles as a potential intravenous hemostat for traumatic hemorrhage control in an animal model
Publication date: Available online 5 September 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Pingyi Zhang, Subo Li, Shikun Zhang, Xue Zhang, Luming Wan, Zhimin Yun, Shouping Ji, Feng Gong, Manna Huang, Leilei Wang, Xinhai Zhu, Yingxia Tan, Yiqian WanAbstractHemostats, which are used for immediate intervention during internal hemorrhage in order to reduce resulting mortality and morbidity, are relatively rare. Here, we describe novel intravenous nanoparticles (CPG-NPs-2000) with chitosan succinate (CSS) as cores, polyethylene glycol (PEG-2000) as spacers and a glycine-arginine-glycine-aspartic aci...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - September 5, 2018 Category: Nanotechnology Source Type: research

An Injectable Hemostat Composed of a Polyphosphate-Conjugated Hyaluronan Hydrogel.
Abstract We have developed a new hydrogel hemostat composed of hyaluronan (HA) conjugated with inorganic polyphosphate (PolyP). A hemostatic hydrogel, HAX-PolyP, was formed rapidly by mixing aldehyde-modified HA and hydrazide-modified HA conjugated with PolyP (HA-PolyP). Although the gelation rate decreased with increasing PolyP content, the gelation time was below 5 min. In addition, the hydrogel swelling volume decreased with increasing PolyP content, but the degradation rate did not depend on PolyP content and the hydrogel underwent complete degradation through hydrolysis over 3 weeks in phosphate buffered sali...
Source: Biomacromolecules - July 9, 2018 Category: Biochemistry Authors: Sakoda M, Kaneko M, Ohta S, Qi P, Ichimura S, Yatomi Y, Ito T Tags: Biomacromolecules Source Type: research

Gel-E wins FDA OTC nod for gel-e Flex flowable hemostat
Early stage wound care company Gel-e said today it won FDA 510(k) clearance for its gel-e Flex as an over-the-counter flowable hemostat. The College Park, Md.-based company said the clearance expands the labeling for the local management of lacerations and minor bleeding, and said the products were specifically designed to be usable by both trained professionals and patients. “This clearance is the next step in expanding our OTC product line, and will be a key component of gel-e’s 21st Century First Aid Kit. We are continuing to develop a tool kit that will provide the best possible options for all manner of...
Source: Mass Device - June 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Wound Care gel-e Source Type: news

Cohera Medical Inc. ® Awarded Patent on its Biodegradable Sealant Technology
Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on its patent application, titled “SILANE-CONTAINING MOISTURE-CURABLE TISSUE SEALANT”.The patent relates to a novel 100% synthetic sealant with several potential surgical applications.  The sealant covered by the patent, Sylys ® Surgical Sealant, is highly elastic, and has good bonding strength to internal tissues.  In addition, the sealant is easy to prepare and apply in the operating theatre and ...
Source: Medical Hemostat - April 25, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt
Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK). Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction. “We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer surgeons additional options that address different situations when intraoperative bleeding can occur,” advanced surgery president Wil Boren said in prepared remarks. “Our top priority right now is wor...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Vascular Wall Street Beat Baxter Mallinckrodt Source Type: news

Convesaid, a Hemostat Powder Spray That Can ’t Cause Embolisms
Team Consulting, a firm based out of an old barn in Cambridge, UK that develops medical devices, one being the EpiPen, has now come up with a hemostat powder sprayer that cannot cause embolisms. When spraying a powder onto a leaking vein, the air tha...
Source: Medgadget - March 16, 2018 Category: Medical Devices Authors: Editors Tags: Cardiac Surgery Emergency Medicine Thoracic Surgery Vascular Surgery Source Type: blogs

Axiostat is India ’ s first entry on the U.S. hemostat market
Indian medical device maker Axio Biosolutions became the first Indian company with a wound care product cleared by the FDA, according to a press release from the company posted yesterday. The federal watchdog granted 510(k) clearance to Axio’s Axiostat chitosan hemostatic dressing, which is cleared as an over-the-counter product to stop external bleeding. The dressing is designed to stop uncontrollable bleeding within two to three minutes of application, and is used by the Indian armed forces, the company said. “The FDA clearance of Axiostat in the US is a major milestone in our journey so far. This is a valida...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Blood Management Regulatory/Compliance Wound Care axiobiosolutions Source Type: news

SURGICEL & #194; & #174; Powder Absorbable Hemostat is used in surgeries.
SURGICEL® Powder Absorbable Hemostat is used for broad-surface oozing and stops bleeding fast. Unit is suitable for gynecologic, oncologic, cardiovascular and general procedure applications. Product offers bactericidal activity in vitro against MRSA, MRSE, VRE, PRSP, E Coli pathogens.This story is related to the following:Hemostats
Source: Industrial Newsroom - Health, Medical and Dental Supplies - January 10, 2018 Category: Medical Devices Source Type: news

New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
SURGICEL® Powder is the next innovation in bleeding management designed to help improve operating efficiency SOMERVILLE, N.J., Jan. 9, 2018 -- (Healthcare Sales & Marketing Network) -- Ethicon*, part of the Johnson & Johnson Medical Devices Compani... Devices, Surgery, Product Launch Ethicon, Johnson & Johnson, SURGICEL, ABSORBABLE HEMOSTAT, hemostat
Source: HSMN NewsFeed - January 9, 2018 Category: Pharmaceuticals Source Type: news

Baxter acquires surgical products
Baxter International Inc., a global medical products company, said Monday that it will acquire two hemostat and sealant products from Mallinckrodt.It will acquire Recothrom Thrombin topical, the first and only stand-alone recombinant thrombin, and Preveleak Surgical Sealant, which is used in vascular reconstruction." Uncontrolled intraoperative bleeding can lead to a wide variety of clinical and economic complications for patients and hospitals. As a leading provider of advanced hemostats and sealants, Deerfield-based Baxter is focused on continually identifying solutions to help meet surgeons ' varying needs, " said Wil B...
Source: Medical Hemostat - January 9, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Hemostasis Solution Controls Bleeding during Surgery
A novel handheld device delivers a powder based on collagen to help surgeons achieve hemostatic bleeding control during surgical procedures.The Biom ’Up (Saint-Priest, France) HemoBlast Bellows is a sterile delivery device that is preloaded with a dry, sterile powder made of highly purified porcine collagen, glucose, chondroitin sulfate, and thrombin. The hemostatic powder is applied to the source of the bleeding by squeezing the bellows. Once applied, the powdered collagen and glucose components start the coagulation process by absorbing blood, concentrating coagulation factors and platelets, and providing a surface for...
Source: Medical Hemostat - January 2, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

---
SAN JOSE, Calif.--(BUSINESS WIRE)--Starch Medical Inc. a privately held manufacturer and marketer of polysaccharide based hemostatic products for use in controlling bleeding in surgery and trauma applications has expanded its product portfolio with the launch of SuperClot ® Hemostat in Europe.Starch Medical received CE Approval earlier this year for SuperClot ® and will utilize their existing network of distribution partners along with new strategic partners to bring this innovative new polymer hemostat solution to surgical teams and hospitals throughout Europe. Next week Starch Medical will exhibit and hold distributor ...
Source: Medical Hemostat - November 8, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cost effectiveness analysis of sealing hemostat patches vs. standard of care in cardiac surgery.
CONCLUSIONS: This analysis supports the use of HEMOPATCH over SOC in cardiac surgery in European hospitals to improve hemostasis success rates and potential cost offsets from reduced transfusions, complications, and surgical revisions. PMID: 29096598 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - November 5, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Scientists Develop Squirtable Glue That Seals Wounds In Seconds
A potentially life-saving surgical glue that is highly elastic and adhesive can quickly seal wounds in seconds without the need for common staples or sutures.The surgical glue, called MeTro, is a development from biomedical engineers at the University of Sydney and biomedical engineers from Harvard University.MeTro has a high elasticity that can seal wounds in body tissues that need to expand and contract continuously, like the lungs, heart and arteries. Wounds on these types of tissues are prone to re-opening after sealing with staples and sutures.The glue is also beneficial for wounds that are in hard-to-reach places tha...
Source: Medical Hemostat - October 25, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Gecko Biomedical receives CE Mark Approval for SETALUM ™ Sealant
Paris, France, September 11, 2017 – Gecko Biomedical (“Gecko”), a medical device company developing innovative polymers to support tissue reconstruction, announced today that it has received CE Mark approval for its SETALUM™ Sealant allowing the company to market its technology in Europe.The SETALUM ™ Sealant is a biocompatible, bioresorbable and on-demand activated sealant usable in wet and dynamic environments as an add-on to sutures during vascular surgery. The polymer is applied to tissue in-situ and activated using a proprietary light activation pen.The technology at the foundation of the SETALUM ™ Sealant...
Source: Medical Hemostat - October 25, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

History of the Hemostat
When trying to achieve hemostasis it is easy to take for granted the convenience of the modern hemostat. Used pervasively in surgery to assist in ligating vessels, its role in hemostasis was initially controversial, and its development spanned thousands of years.
Source: JAMA Dermatology - September 1, 2017 Category: Dermatology Source Type: research

TissuGlu ® Surgical Adhesive enables drain-free recovery in patients undergoing DIEP flap breast reconstruction
RALEIGH, N.C., June 08, 2017 -- Outcomes of the SANA Gerresheim series demonstrated that effective donor-site flap closure with TissuGlu Surgical Adhesive is a viable alternative to post-surgical drains. Dr. Sonia Fertsch presented the series, which included 41 DIEP flap breast reconstructions, at the EURAPS Research Council Meeting in Pisa last month. The annual event allows young surgeons to present top research initiatives to an audience of plastic surgeons and researchers from around the world. During a DIEP flap reconstruction, blood vessels, skin and fat of the lower abdomen are removed and utilized to reco...
Source: Medical Hemostat - June 9, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Snake venom is key ingredient in experimental drug for heart patients
An experimental antiplatelet drug has surprising bite. Based on a protein found in snake venom, the new drug prevented blood clotting in mice without causing excessive bleeding after an injury, according to research published Thursday in the journal Arteriosclerosis, Thrombosis and Vascular Biology. The drug has yet to be tested in humans.Bleeding is a common side effect in the current crop of available antiplatelet drugs, which are usually prescribed for heart patients to prevent blood cells, called platelets, from clumping together and forming clots. Depending on where they occur, clots can lead to a stroke or heart atta...
Source: Medical Hemostat - June 9, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

FDA clears Ethicon ’ s Surgicel powdered hemostat
Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today it won FDA approval for its Surgicel powder absorbable hemostat designed as an adjunctive hemostatic solution to control continuous oozing on broad or raw surfaces. The Surgicel powdered hemostat is comprised of oxidized regenerated cellulose, the base component in all of its Surgicel products. The powdered solution comes with an applicator and is designed to penetrate through oozing blood and form clots that stay intact even when the surgical field is irrigated, Ethicon said. “This new and innovative approach to applying ORC, combined with the proven tr...
Source: Mass Device - June 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Food & Drug Administration (FDA) Regulatory/Compliance Surgical Ethicon Johnson & Johnson Source Type: news

Ethicon Announces FDA Approval For SURGICEL(R) Powder Absorbable Hemostat
SOMERVILLE, N.J., June 6, 2017 -- (Healthcare Sales & Marketing Network) -- Uncontrolled bleeding during surgery can adversely affect patient outcomes, hospital costs and resources.1-9 Primary methods of hemostasis alone may be ineffective or impractical,... Devices, Surgery, FDA Ethicon, SURGICEL, Powder Absorbable Hemostat
Source: HSMN NewsFeed - June 6, 2017 Category: Pharmaceuticals Source Type: news

Hemostatic agents market is estimated to reach USD 8,347.9 Million by 2022
Surgery is a foundational component of health-care systems. Over 51 million hospital-based surgical procedures are performed annually worldwide. The effective management of bleeding to achieve hemostasis during surgical procedures is essential to promote positive outcomes. As surgical procedures evolve to be more refined and noninvasive, the utilization of fast acting biologically and synthetically derived hemostats, encompassing fibrin sealants, flowable gelatins and adhesives, is becoming increasingly prevalent. Some of the parameters for choosing a hemostatic agent includes efficiency, type of surgery, patient condition...
Source: Medical Hemostat - June 2, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Porous chitosan microspheres for application as quick in vitro and in vivo hemostat
We reported the fabrication of porous chitosan microspheres (CSMS) with tunable surface pore size by microemulsion combined with thermally induced phase separation technique, and its application as a quick hemostat. Their hemostatic property was characterized by blood clotting kinetics, adherence interaction between red blood cells/platelets and CSMS, in vitro and in vivo hemostasis by rat tail amputation and liver laceration models, and histological analysis. Their density, surface area, porosity, water absorption ratio were 0.04–0.06g/cm3, 28.2–31.5m2/g, 98%, and 15.5–23.2g/g, respectively. The surface pore was con...
Source: Materials Science and Engineering: C - April 4, 2017 Category: Materials Science Source Type: research

Starch-derived absorbable polysaccharide hemostat enhances bone healing via BMP-2 protein.
In this study, we used a model of rabbit parietal bone defect and a mouse osteoblast cell line MC3T3-E1 to evaluate the effects of SAPH on bone healing. We found that SAPH significantly decreased bone healing scores, reduced defective area of parietal bone, and increased the areas of bone trabeculae and cavitas medullaris. In addition, SAPH enhanced MC3T3-E1 osteoblasts proliferation, up-regulated the expressions of alkaline phosphatase (ALP) and osteocalcin and increased the level of bone morphogenetic protein 2 (BMP-2) in MC3T3-E1 osteoblasts. These SAPH-induced benefits in MC3T3-E1 osteoblasts were significantly abolish...
Source: Acta Histochemica - February 3, 2017 Category: Biochemistry Authors: Niu W, Wang Y, Liu Y, Zhang B, Liu M, Luo Y, Zhao P, Zhang Y, Wu H, Ma L, Li Z Tags: Acta Histochem Source Type: research

Fibrin Glue Market: Asia is expected to witness high growth rates in the next five years, 2021
Fibrin glue is a unique adhesion material used in surgeries for closure of wounds. Fibrin glues are mainly extracted from collective plasma and contain different amounts of purified and virally-inactivated human proteins. Fibrin glue is composed of two components, including fibrinogen and factor XIII. These concentrated ingredients interact with a solution of thrombin and calcium to form coagulum. As the thrombin and fibrinogen/factor XIII solution combine, a clot of a blood protein called fibrin develops in a few seconds, depending on the dilute form of thrombin is used. Some of the characteristics of fibrin glue include ...
Source: Medical Hemostat - November 20, 2016 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

PENTAX Unveils HemoStat WideCup Bipolar Hot Hemostasis Forceps
PENTAX Medical, a part of HOYA Group, has unveiled its new HemoStat WideCup bipolar hot hemostasis forceps for use during endoscopies. Designed to stop bleeding in an efficient and safe manner, the device features an opening width considerably wider ...
Source: Medgadget - November 8, 2016 Category: Medical Equipment Authors: Editors Tags: GI Source Type: blogs

HOYA Group PENTAX Medical Launch HemoStat WideCup(TM), The New Bipolar Hot Hemostasis Forceps Contributing to Early Treatment of Gastric Cancer
TOKYO, Nov. 2, 2016 -- (Healthcare Sales & Marketing Network) -- HOYA Group PENTAX Medical has launched HemoStat WideCupTM, the new bipolar hot hemostasis forceps to achieve easy control of bleeding during endoscopic therapy procedures. The new device wi... Devices, Oncology, Product Launch PENTAX Medical, HOYA Group, HemoStat WideCup, hemostasis, endoscopy
Source: HSMN NewsFeed - November 2, 2016 Category: Pharmaceuticals Source Type: news

Efficacy of TachoSil, a Fibrin-Based Hemostat, for Anterior Lumbar Spine Surgery.
CONCLUSIONS: We recommend the use of TachoSil for vessel injuries that vascular surgeons cannot suture or repair during ALF surgery. PMID: 27790323 [PubMed - in process]
Source: Asian Spine Journal - October 31, 2016 Category: Orthopaedics Tags: Asian Spine J Source Type: research

“Hemostat forceps” a simple and useful adjuvant to clip applicator forceps for clipping saccular cerebral aneurysms – Technical note
Publication date: December 2016 Source:Interdisciplinary Neurosurgery, Volume 6 Author(s): Mahesh Krishna Pillai, Smitha Thankappan Nair Despite technical and technological advances in Neurosurgery, in the last four decades, there has been no significant reduction, in the dimensions of the, aneurysm clip applicator forceps. This can be challenging, even to the most experienced neurovascular surgeon, especially when the surgical corridor created remains narrow, despite all possible measures to widen it. The author describes one such situation, where an anterior communicating artery aneurysm was clipped successfully using a...
Source: Interdisciplinary Neurosurgery - October 14, 2016 Category: Neurosurgery Source Type: research

"Hemostat Forceps" A Simple and Useful Adjuvant to Clip Applicator Forceps for Clipping Saccular Cerebral Aneurysms – Technical note
Publication date: Available online 12 September 2016 Source:Interdisciplinary Neurosurgery Author(s): Mahesh Krishna Pillai Despite technical and technological advances in Neurosurgery, in the last four decades, there has been no significant reduction, in the dimensions of the, aneurysm clip applicator forceps. This can be challenging, even to the most experienced neurovascular surgeon, especially when the surgical corridor created remains narrow, despite all possible measures to widen it. The author describes one such situation, where an anterior communicating artery aneurysm was clipped successfully using a simple “he...
Source: Interdisciplinary Neurosurgery - September 12, 2016 Category: Neurosurgery Source Type: research

Arch Therapeutics launches EU trial for AC5 hemostat
Arch Therapeutics (OTC:ARTH) said today that it launched a European safety-and-efficacy study of its AC5 surgical hemostat in bleeding wounds incurred during dermatology procedures. Framingham, Mass.-based Arch, which won approval for the randomized, controlled, single-blind study last December, said the 46-patient trial will include a 10-subject arm who are taking blood thinners. Each patient will have at least 2 lesions removed, with 1 wound treated using the AC5 hemostat and the 2nd with a control treatment. Arch bills AC5 as designed to stop bleeding in seconds, rather than minutes, and conform to wound geometries wh...
Source: Mass Device - March 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Surgical Arch Therapeutics Source Type: news

Hemostasis and Tissue Sealing Agents Market to Experience Significant Growth Due to Aggressive Marketing Strategies
The global hemostasis and tissue sealing agents market signifies the market for sophisticated hemostat medical devices. These devices are utilized to control excessive bleeding in operations and surgeries and have significant roles in assisting healing processes in surgical procedures. Introduction of New Products Driving Hemostasis and Tissue Sealing Agents MarketThe hemostasis and tissue sealing agents market is going through a steady growth phase. The major companies in the hemostasis and tissue sealing agents industry are adopting aggressive marketing strategies to increase their product penetration rate in the ma...
Source: Medical Hemostat - August 25, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Johnson & Johnson (JNJ) Announces Additional FDA Indication for EVARREST Fibrin Sealant Patch
Johnson & Johnson (NYSE: JNJ) announced the following Monday:Unexpected and uncontrollable bleeding is an ongoing challenge for surgeons, including those who perform liver surgery. Based on recent data, the U.S. Food and Drug Administration has approved an additional indication for Ethicon's EVARREST Fibrin Sealant Patch, as an adjunct to hemostasis for control of bleeding during adult liver surgery. EVARREST is a novel convergence of biologics and medical device that rapidly and reliably stops problematic bleeding during surgery on the first attempt in indicated patients.A problematic bleeding situation—involving bl...
Source: Medical Hemostat - April 6, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Johnson & Johnson (JNJ) Announces Additional FDA Indication for EVARREST Fibrin Sealant Patch
Johnson & amp; Johnson (NYSE: JNJ) announced the following Monday: Unexpected and uncontrollable bleeding is an ongoing challenge for surgeons, including those who perform liver surgery. Based on recent data, the U.S. Food and Drug Administration has approved an additional indication for Ethicon ' s EVARREST Fibrin Sealant Patch, as an adjunct to hemostasis for control of bleeding during adult liver surgery. EVARREST is a novel convergence of biologics and medical device that rapidly and reliably stops problematic bleeding during surgery on the first attempt in indicated patients. A problematic bleeding situation —...
Source: Medical Hemostat - April 6, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

HaemoCer approved for use in China and Canada
BioCer Entwicklungs GmbH (BCE), a German implantable biological medical device development and manufacturing company, announced today that it has achieved approval to commence sales of HaemoCer™, an Absorbable Polysaccharide Hemostat (APH), in the People's Republic of China."BioCer has now achieved near comprehensive Asia-Pacific regional representation, and the addition of the PRC approval of HaemoCer™ is a significant milestone," Dr Markus Heinlein, Managing Director stated. "The entry into China of our first product HaemoCer™ has been assisted by the early establishment of region...
Source: Medical Hemostat - October 8, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product.Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries.“Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica’s Pre...
Source: Medical Hemostat - May 5, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol ®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product. Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries. “Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica...
Source: Medical Hemostat - May 5, 2014 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio Acquires Tenaxis Medical, Inc.
PARSIPPANY, NJ and MOUNTAIN VIEW, CA -- (Marketwired) -- 04/23/14 -- The Medicines Company (NASDAQ: MDCO) and Tenaxis Medical, Inc. (Tenaxis) today announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received US PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. The addition of the Tenaxis product adds another so...
Source: Medical Hemostat - April 23, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

FDA Accepts Biologic License Application for Fibrocaps Hemostatic Agent
The Medicines Company has announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date (PDUFA date) for Fibrocaps is January 31, 2015. In August 2013, The Medicines Company announced that the Phase III trial, FINISH-3, which studied a total of 719 patients across 54 sites in the U.S. and W...
Source: Medical Hemostat - April 5, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs